Integra LifeSciences Holdings Corporation
IART
$9.55
-$0.02-0.21%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.74% | 5.57% | -0.61% | 3.74% | 11.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.74% | 5.57% | -0.61% | 3.74% | 11.49% |
| Cost of Revenue | 10.21% | 5.79% | 11.36% | 12.41% | 9.13% |
| Gross Profit | -9.36% | 5.41% | -8.61% | -2.14% | 13.04% |
| SG&A Expenses | -2.89% | 1.21% | -2.65% | 2.81% | 22.48% |
| Depreciation & Amortization | 1.43% | -0.85% | 1.27% | 21.72% | 22.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.90% | 1.82% | 3.22% | 6.94% | 16.49% |
| Operating Income | -21.50% | 58.76% | -30.74% | -22.28% | -9.57% |
| Income Before Tax | -80.88% | 66.49% | -3,396.56% | -474.30% | -21.89% |
| Income Tax Expenses | 93.63% | 85.31% | -1,584.48% | -143.36% | -65.58% |
| Earnings from Continuing Operations | -108.77% | 49.47% | -3,803.18% | -670.89% | -2.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.77% | 49.47% | -3,803.18% | -670.89% | -2.01% |
| EBIT | -21.50% | 58.76% | -30.74% | -22.28% | -9.57% |
| EBITDA | -18.55% | 28.36% | -8.44% | -3.38% | 5.98% |
| EPS Basic | -108.73% | 49.68% | -3,839.89% | -683.89% | -0.04% |
| Normalized Basic EPS | -37.13% | 61.07% | -55.90% | -42.28% | -18.40% |
| EPS Diluted | -109.10% | 49.71% | -3,839.89% | -683.89% | 0.40% |
| Normalized Diluted EPS | -37.13% | 61.07% | -55.90% | -42.28% | -18.40% |
| Average Basic Shares Outstanding | 0.47% | 0.40% | -0.92% | -1.64% | -1.98% |
| Average Diluted Shares Outstanding | 0.47% | 0.40% | -0.92% | -1.64% | -1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |